Table of Contents 2
List of Tables 4
List of Figures 4
Morphotek, Inc. Spshot 5
Morphotek, Inc. Overview 5
Key Information 5
Key Facts 5
Morphotek, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Morphotek, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Morphotek, Inc. - Pipeline Products Glance 11
Morphotek, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combition Treatment Modalities 11
Phase I Products/Combition Treatment Modalities 12
Morphotek, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combition Treatment Modalities 13
Morphotek, Inc. - Drug Profiles 14
amatuximab 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
farletuzumab 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ontuxizumab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
KAb-071 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MORAb-022 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MORAb-066 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclol Antibody Conjugates for Oncology 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MORAb-047 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MORAb-048 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MORAb-050 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MORAb-075 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Morphotek, Inc. - Pipeline Alysis 30
Morphotek, Inc. - Pipeline Products by Target 30
Morphotek, Inc. - Pipeline Products by Route of Administration 31
Morphotek, Inc. - Pipeline Products by Molecule Type 32
Morphotek, Inc. - Pipeline Products by Mechanism of Action 33
Morphotek, Inc. - Recent Pipeline Updates 34
Morphotek, Inc. - Dormant Projects 38
Morphotek, Inc. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41